Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Another epic EPO battle

A summary judgment last week appeared to give Amgen Inc. the upper hand leading into its Sept. 4 trial date in a patent infringement lawsuit against Roche related to erythropoiesis-stimulating agents. But even though AMGN's patents are battle-tested, the validity of one is still up in the air

Read the full 485 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers